The effect of the Medicare Part D prescription benefit on drug utilization and expenditures.
about
Pharmaceutical policies: effects of cap and co-payment on rational use of medicinesThe impact of the Medicare Part D prescription benefit on generic drug useImpact of Medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expendituresMedicare Part D and quality of prescription medication use in older adultsThe impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utilityComparison friction: experimental evidence from medicare drug plansCompleteness of retail pharmacy claims data: implications for pharmacoepidemiologic studies and pharmacy practice in elderly patientsSocioeconomic Disparities in Mortality Among Women With Incident Breast Cancer Before and After Implementation of Medicare Part DPrescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study.Medicare Part D coverage gap and diabetes beneficiaries.Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetesEffects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?How the Medicare Part D drug benefit changed the distribution of out-of-pocket pharmacy spending among older beneficiaries.Nursing home residents and enrollment in Medicare Part D.The Medicare drug benefit (Part D) and treatment of heart failure in older adults.Healthcare reform in the United States and China: pharmaceutical market implicationsRisk factors of self-reported adverse drug events among Medicare enrollees before and after Medicare Part D.Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic reviewTake-up of Medicare Part D: results from the Health and Retirement Study.The impact of Medicare Part D on medication treatment of hypertension.Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: a longitudinal analysis.From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination.Awareness of pharmaceutical cost-assistance programs among inner-city seniors.Medicare part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007The impact of Medicare Part D on hospitalization ratesDrug benefit changes under Medicare Advantage Part D: heterogeneous effects on pharmaceutical use and expendituresFactors Associated with Persistence with Teriparatide Therapy: Results from the DANCE Observational StudyInsurers' Negotiating Leverage and the External Effects of Medicare Part DImpact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression.Reconsideration of key articles regarding medication-related problems in older adults from 2011.Ethnic disparities in adherence to antihypertensive medications of medicare part D beneficiaries.Medicare part D's impact on antipsychotic drug use and costs among elderly patients without prior drug insurance.Universal drug coverage and socioeconomic disparities in major diabetes outcomesTHE RESPONSE OF DRUG EXPENDITURE TO NON-LINEAR CONTRACT DESIGN: EVIDENCE FROM MEDICARE PART D.Medicare Part D and potentially inappropriate medication use in the elderly.Recent trends in cost-related medication nonadherence among stroke survivors in the United StatesCost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries.Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development.Potential bias in medication adherence studies of prevalent users.Medicare part D after 2 years.
P2860
Q24188009-9D6DC217-8F02-4069-BB25-CF1558F4C35DQ24652400-0714C473-78CC-4B40-AC96-DF9E674CC2CEQ24655747-AF834106-2623-4718-AB3D-3379DD0C11F3Q27023843-E49D0577-F060-4F36-B47E-55847A737AEBQ28238484-83F00D9C-08E0-4CC3-95EE-15959DA69F4EQ28730897-87D7F9E2-9782-46F6-9347-C8C21A53E8D9Q33511568-DCC15953-6246-49D5-8791-A56E34749F6AQ33563718-F066677A-0BBF-46A8-A0F9-3AC3AF7C226EQ33611387-C5BE8960-60C7-466B-A8AE-3F437EA01C29Q33667931-31B87CC6-AB76-4864-8AA0-05BBBE33DB89Q33725773-65C0DB47-3E5F-4BC4-B4EB-C09CAA39157DQ33865820-FCB57074-EB2A-413B-9B28-81FCE2C0DBE6Q33906706-88A7BF5D-9115-4EEA-B348-8A9DE34D7A56Q33946903-208DA415-65F2-4779-9240-8D052E6832D5Q33967679-A16DA682-E1BD-418F-AD80-0501E87725A1Q33984685-56699474-D531-4DF8-B0B4-03A8B2AF32F9Q34053163-3506BE7B-D639-44D1-AF2A-02A4C99609DCQ34158480-83B355D1-7E00-4151-886F-EADB0771DFCDQ34400363-F2F63282-9C8F-4606-87A7-8ECBD2E4B9ABQ34554697-43846ADA-676B-4542-A6DD-56B96FCC238FQ34556420-60752E77-09D0-4CD8-8C54-E58DCE62C3EBQ34613417-4F3B3E80-0216-4E2D-A6A8-9F16A1C2448FQ34981370-2086E687-FD83-495A-86E3-6CBD4D3DDF9FQ35151469-E270DC41-40F7-4343-A2B2-16D76345CEE7Q35190976-17F97C49-4338-45CB-89C8-9F6F8A5B7592Q35235565-4B9EE3FF-34A6-4F04-9A00-1D2029399D97Q35371081-12BD68AA-83B9-44AD-BB31-079E9BC3C699Q35552508-E0CBEF83-1B6D-44C6-8931-8548B764495EQ35602002-53C935DD-133E-4BFE-9FFB-6E51ECDE14C0Q36043785-4AA34210-0587-4324-B85A-DA7C2E68F12EQ36094813-D8065E01-4580-49DB-BD7A-E8088F6477C8Q36165497-AE254724-8A9A-4EEF-9DED-ABE4A2C8AF7EQ36334609-3AC65C69-102F-4D2C-9A53-A9AA5D4B0694Q36455637-EC13D422-E528-4896-B8C6-B5A5472D8AEFQ36755390-AFE4FD71-DEF2-4F3B-B467-6ED5A1B7E7D0Q36916381-3051EA88-5C21-42B3-8EA3-18874464B622Q36927439-6E092725-8004-4A98-9D55-EE97CC5CBC50Q37014496-375E234A-85A4-4A61-9464-8C7529EAF067Q37050974-1DADF186-FB76-4500-8E9D-C3C25700E2ABQ37157070-34AFB8E9-C607-439A-9637-F76F8871F230
P2860
The effect of the Medicare Part D prescription benefit on drug utilization and expenditures.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
The effect of the Medicare Par ...... utilization and expenditures.
@en
The effect of the Medicare Par ...... utilization and expenditures.
@nl
type
label
The effect of the Medicare Par ...... utilization and expenditures.
@en
The effect of the Medicare Par ...... utilization and expenditures.
@nl
prefLabel
The effect of the Medicare Par ...... utilization and expenditures.
@en
The effect of the Medicare Par ...... utilization and expenditures.
@nl
P2093
P1476
The effect of the Medicare Par ...... g utilization and expenditures
@en
P2093
Anirban Basu
David O Meltzer
G Caleb Alexander
James X Zhang
Wesley Yin
P304
P356
10.7326/0003-4819-148-3-200802050-00200
P407
P577
2008-01-07T00:00:00Z